5 research outputs found
Acinetobacter Baumannii Pneumonia Associated with Mechanical Ventilation in COVID-19 Pandemic
Infekcije uzrokovane bakterijom Acinetobacter baumannii predstavljaju veliki javnozdravstveni problem. Acinetobacter baumannii kontaminira bolniÄko okruženje, kožu i sluznice pacijenata te se prenosi rukama osoblja uzrokujuÄi oportunistiÄke infekcije kao Å”to su upale pluÄa povezane s mehaniÄkom ventilacijom, bakterijemije, infekcije rana te urinarne infekcije. Ventilatorom uzrokovana upala pluÄa druga je po uÄestalosti nozokomijalna infekcija u jedinicama intenzivnog lijeÄenja. VodeÄi Äimbenik rizika za razvoj ventilatorom uzrokovane upale pluÄa jest invazivna mehaniÄka ventilacija. U pacijenata s boleÅ”Äu COVID-19, lijeÄenje u jedinicama intenzivnog lijeÄenja Äesto je zahtijevalo intubaciju i uporabu mehaniÄke ventilacije izlažuÄi ih riziku od razvoja ventilatorom uzrokovane upale pluÄa. S obzirom na brojna preklapanja u kliniÄkoj slici COVID upale pluÄa i upale pluÄa povezane s ventilatorom, teÅ”ko je sa sigurnoÅ”Äu odrediti njezinu prevalenciju. OÅ”teÄenja pluÄa uzrokovana boleÅ”Äu COVID-19, imunosupresivna terapija, Äesto profilaktiÄko koriÅ”tenje antibiotika i organizacijske teÅ”koÄe ā prenapuÄenost u jedinicama intenzivnog lijeÄenja, manjak osoblja, potreba za zaÅ”titom osoblja od virusa SARS-CoV-2 (engl. Severe acute respiratory syndrome coronavirus 2) infekcije i dr., pridonijeli su poveÄanoj pojavnosti ventilatorom izazvane upale pluÄa uzrokovane Acinetobacter baumannii u pacijenata oboljelih od COVID-a. Brojni mehanizmi otpornosti na antibiotike, uz posljediÄno sve veÄu prevalenciju viÅ”estruko otpornih sojeva Acinetobacter baumannii predstavljaju izazov u lijeÄenju. U osjetljivih sojeva, monoterapija karbapenemima dovodi do pozitivnog ishoda. LijeÄenje karbapenem-otpornih Acinetobacter baumannii sojeva u kompliciranim infekcijama provodi se uglavnom kolistinom. Kolistin se može primjenjivati intravenski i inhalacijski te ga se preporuÄuje koristiti u kombinaciji s drugim djelotvornim antibioticima.Infections caused by Acinetobacter baumannii are a major public health issue. Acinetobacter baumannii contaminates the hospital environment, skin, and mucous membranes of patients and is transmitted by the hands of staff, causing opportunistic infections such as pneumonia associated with mechanical ventilation, bacteremia, wound infections, and urinary tract infections. Ventilator-associated pneumonia is the second most common nosocomial infection in the intensive care units. The leading risk factor for the development of ventilator-associated pneumonia is invasive mechanical ventilation. In the patients with COVID-19 disease, the treatment in intensive care units often required intubation and the use of mechanical ventilation, exposing them to the risk of developing ventilator-associated pneumonia. Given the numerous overlaps in the clinical picture of COVID-19 pneumonia and ventilator-associated pneumonia, it is difficult to determine its prevalence with certainty. Lung damage caused by COVID-19, immunosuppressive therapy, frequent prophylactic use of antibiotics, and organizational difficulties (overcrowding in intensive care units, staff shortages, the need to protect staff from severe acute respiratory syndrome coronavirus 2 infection, etc.) have contributed to the increased incidence of ventilator-associated pneumonia in COVID-19 patients. Numerous mechanisms of antibiotic resistance and the increasing prevalence of multidrug-resistant strains such as carbapenem-resistant Acinetobacter baumannii present a challenge in treatment. In susceptible strains, monotherapy with carbapenems leads to a positive outcome. The treatment of carbapenem-resistant Acinetobacter baumannii strains in complicated infections is carried out mainly with colistin. Colistin can be administered intravenously or by inhalation, and itās use in combination with other effective antibiotics is recommended
Six minute walk test in children with cystic fibrosis before and during treatment with cystic fibrosis transmembrane conductance regulator modulators
Uvod. NaruÅ”ena tjelesna spremnost bitno negativno utjeÄe na kvalitetu života oboljelih od cistiÄne fibroze (CF). Može se procijeniti Å”est-minutnim testom hoda (6MWT).
Cilj istraživanja. Istražiti povezanost primjene modulatora transmembranskog regulatora provodljivosti za CF (CFTR) s poboljŔanjem tjelesne spremnosti.
Metode. Ovo retrospektivno istraživanje provedeno je s podatcima prikupljenim od maloljetnih bolesnika ā„ 5 god. koji su u razdoblju od 15. 10. 2021. do 30. 10. 2022. zapoÄeli lijeÄenje eleksakaftorom/tezakaftorom/ivakaftorom (ELX/TEZ/IVA) ili lumakaftorom/ivakaftorom (LUM/IVA) u Centru za cistiÄnu fibrozu djece i odraslih KliniÄkog bolniÄkog centra Zagreb. Ispitanici su praÄeni prvih 12 mjeseci lijeÄenja te im je svaka tri mjeseca odreÄen indeks tjelesne mase (BMI), uÄinjena spirometrija i 6MWT. PraÄena je promjena navedenih parametara u tom razdoblju te meÄuodnos rezultata 6MWT-a i BMI-ja, odnosno pluÄne funkcije. Nedostajali podatci nadomjeÅ”teni su primjenom imputacije.
Rezultati. 36 bolesnika (medijan dobi 14 god.) ukljuÄeno je u istraživanje; njih 27 lijeÄeno s ELX/TEZ/IVA, a 9 s LUM/IVA. ProsjeÄna duljina hodne pruge na poÄetku lijeÄenja iznosila je 522,1 Ā± 99,9 m, a nakon 12 mjeseci 592,0 Ā± 106,3 m (p < 0,001). Pritom je najveÄe poveÄanje duljine hodne pruge bilo zabilježeno u prvih Å”est mjeseci lijeÄenja (p = 0,023). Promjena z-vrijednosti BMI-ja (p = 0,006) i postotka prediktivne vrijednosti FEV1 (ppFEV1) (p < 0,001) tijekom 12 mjeseci praÄenja takoÄer je bila znaÄajna. Duljina hodne pruge nakon 12 mjeseci lijeÄenja pozitivno je korelirala sa z-vrijednoÅ”Äu BMI-ja (p = 0,002) i ppFEV1 (p < 0,001).
ZakljuÄak. LijeÄenje CFTR modulatorima praÄeno je i kliniÄki i statistiÄki znaÄajnim poboljÅ”anjem tjelesne spremnosti uz pozitivnu korelaciju s poboljÅ”anjem uhranjenosti i pluÄne funkcije.Background. Exercise tolerance is compromised in many patients with cystic fibrosis (CF) and negatively affects their quality of life. The six-minute walk test (6MWT) can be used to assess exercise tolerance.
Aim. To investigate whether cystic fibrosis transmembrane conductance regulator (CFTR) modulators are associated with an improvement in exercise tolerance.
Methods. This is a retrospective study including children aged ā„ 5 years who began treatment with lumacaftor/ivacaftor (LUM/IVA) or elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) at the Cystic Fibrosis Centre for Children and Adults at the University Hospital Centre Zagreb in the period between 15. 10. 2021. and 30. 10. 2022. Patients were monitored during the first 12 months of treatment; every 3 months body mass index (BMI) was calculated and spirometry and 6MWT were performed. Collected data were analysed for a change in 6MWT results, BMI and percent-predicted FEV1 (ppFEV1) as well as correlation between these parameters. Missing values were replaced using imputation methods.
Results. 36 patients (median age 14 years) were included; 27 received ELX/TEZ/IVA and 9 received LUM/IVA. Average 6MWT walking distance (6MWD) prior to treatment and after 12 months were 522.1 Ā± 99.9 and 592.0 Ā± 106.3 m respectively (p < 0.001). Average increase in 6MWD in the first half-year was significantly higher than in the following 6 months (p = 0.023). Changes in BMI z-score (p = 0.006) and ppFEV1 (p < 0.001) during treatment were also significant. 6MWD at 12 months positively correlated with BMI z-score (p = 0.002) and ppFEV1 (p < 0.001).
Conclusions. Both clinically and statistically significant improvement in 6MWT results was visible following initiation of CFTR modulator treatment. A positive correlation with lung function improvement and improvement in BMI was observed
Six minute walk test in children with cystic fibrosis before and during treatment with cystic fibrosis transmembrane conductance regulator modulators
Uvod. NaruÅ”ena tjelesna spremnost bitno negativno utjeÄe na kvalitetu života oboljelih od cistiÄne fibroze (CF). Može se procijeniti Å”est-minutnim testom hoda (6MWT).
Cilj istraživanja. Istražiti povezanost primjene modulatora transmembranskog regulatora provodljivosti za CF (CFTR) s poboljŔanjem tjelesne spremnosti.
Metode. Ovo retrospektivno istraživanje provedeno je s podatcima prikupljenim od maloljetnih bolesnika ā„ 5 god. koji su u razdoblju od 15. 10. 2021. do 30. 10. 2022. zapoÄeli lijeÄenje eleksakaftorom/tezakaftorom/ivakaftorom (ELX/TEZ/IVA) ili lumakaftorom/ivakaftorom (LUM/IVA) u Centru za cistiÄnu fibrozu djece i odraslih KliniÄkog bolniÄkog centra Zagreb. Ispitanici su praÄeni prvih 12 mjeseci lijeÄenja te im je svaka tri mjeseca odreÄen indeks tjelesne mase (BMI), uÄinjena spirometrija i 6MWT. PraÄena je promjena navedenih parametara u tom razdoblju te meÄuodnos rezultata 6MWT-a i BMI-ja, odnosno pluÄne funkcije. Nedostajali podatci nadomjeÅ”teni su primjenom imputacije.
Rezultati. 36 bolesnika (medijan dobi 14 god.) ukljuÄeno je u istraživanje; njih 27 lijeÄeno s ELX/TEZ/IVA, a 9 s LUM/IVA. ProsjeÄna duljina hodne pruge na poÄetku lijeÄenja iznosila je 522,1 Ā± 99,9 m, a nakon 12 mjeseci 592,0 Ā± 106,3 m (p < 0,001). Pritom je najveÄe poveÄanje duljine hodne pruge bilo zabilježeno u prvih Å”est mjeseci lijeÄenja (p = 0,023). Promjena z-vrijednosti BMI-ja (p = 0,006) i postotka prediktivne vrijednosti FEV1 (ppFEV1) (p < 0,001) tijekom 12 mjeseci praÄenja takoÄer je bila znaÄajna. Duljina hodne pruge nakon 12 mjeseci lijeÄenja pozitivno je korelirala sa z-vrijednoÅ”Äu BMI-ja (p = 0,002) i ppFEV1 (p < 0,001).
ZakljuÄak. LijeÄenje CFTR modulatorima praÄeno je i kliniÄki i statistiÄki znaÄajnim poboljÅ”anjem tjelesne spremnosti uz pozitivnu korelaciju s poboljÅ”anjem uhranjenosti i pluÄne funkcije.Background. Exercise tolerance is compromised in many patients with cystic fibrosis (CF) and negatively affects their quality of life. The six-minute walk test (6MWT) can be used to assess exercise tolerance.
Aim. To investigate whether cystic fibrosis transmembrane conductance regulator (CFTR) modulators are associated with an improvement in exercise tolerance.
Methods. This is a retrospective study including children aged ā„ 5 years who began treatment with lumacaftor/ivacaftor (LUM/IVA) or elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) at the Cystic Fibrosis Centre for Children and Adults at the University Hospital Centre Zagreb in the period between 15. 10. 2021. and 30. 10. 2022. Patients were monitored during the first 12 months of treatment; every 3 months body mass index (BMI) was calculated and spirometry and 6MWT were performed. Collected data were analysed for a change in 6MWT results, BMI and percent-predicted FEV1 (ppFEV1) as well as correlation between these parameters. Missing values were replaced using imputation methods.
Results. 36 patients (median age 14 years) were included; 27 received ELX/TEZ/IVA and 9 received LUM/IVA. Average 6MWT walking distance (6MWD) prior to treatment and after 12 months were 522.1 Ā± 99.9 and 592.0 Ā± 106.3 m respectively (p < 0.001). Average increase in 6MWD in the first half-year was significantly higher than in the following 6 months (p = 0.023). Changes in BMI z-score (p = 0.006) and ppFEV1 (p < 0.001) during treatment were also significant. 6MWD at 12 months positively correlated with BMI z-score (p = 0.002) and ppFEV1 (p < 0.001).
Conclusions. Both clinically and statistically significant improvement in 6MWT results was visible following initiation of CFTR modulator treatment. A positive correlation with lung function improvement and improvement in BMI was observed
Six minute walk test in children with cystic fibrosis before and during treatment with cystic fibrosis transmembrane conductance regulator modulators
Uvod. NaruÅ”ena tjelesna spremnost bitno negativno utjeÄe na kvalitetu života oboljelih od cistiÄne fibroze (CF). Može se procijeniti Å”est-minutnim testom hoda (6MWT).
Cilj istraživanja. Istražiti povezanost primjene modulatora transmembranskog regulatora provodljivosti za CF (CFTR) s poboljŔanjem tjelesne spremnosti.
Metode. Ovo retrospektivno istraživanje provedeno je s podatcima prikupljenim od maloljetnih bolesnika ā„ 5 god. koji su u razdoblju od 15. 10. 2021. do 30. 10. 2022. zapoÄeli lijeÄenje eleksakaftorom/tezakaftorom/ivakaftorom (ELX/TEZ/IVA) ili lumakaftorom/ivakaftorom (LUM/IVA) u Centru za cistiÄnu fibrozu djece i odraslih KliniÄkog bolniÄkog centra Zagreb. Ispitanici su praÄeni prvih 12 mjeseci lijeÄenja te im je svaka tri mjeseca odreÄen indeks tjelesne mase (BMI), uÄinjena spirometrija i 6MWT. PraÄena je promjena navedenih parametara u tom razdoblju te meÄuodnos rezultata 6MWT-a i BMI-ja, odnosno pluÄne funkcije. Nedostajali podatci nadomjeÅ”teni su primjenom imputacije.
Rezultati. 36 bolesnika (medijan dobi 14 god.) ukljuÄeno je u istraživanje; njih 27 lijeÄeno s ELX/TEZ/IVA, a 9 s LUM/IVA. ProsjeÄna duljina hodne pruge na poÄetku lijeÄenja iznosila je 522,1 Ā± 99,9 m, a nakon 12 mjeseci 592,0 Ā± 106,3 m (p < 0,001). Pritom je najveÄe poveÄanje duljine hodne pruge bilo zabilježeno u prvih Å”est mjeseci lijeÄenja (p = 0,023). Promjena z-vrijednosti BMI-ja (p = 0,006) i postotka prediktivne vrijednosti FEV1 (ppFEV1) (p < 0,001) tijekom 12 mjeseci praÄenja takoÄer je bila znaÄajna. Duljina hodne pruge nakon 12 mjeseci lijeÄenja pozitivno je korelirala sa z-vrijednoÅ”Äu BMI-ja (p = 0,002) i ppFEV1 (p < 0,001).
ZakljuÄak. LijeÄenje CFTR modulatorima praÄeno je i kliniÄki i statistiÄki znaÄajnim poboljÅ”anjem tjelesne spremnosti uz pozitivnu korelaciju s poboljÅ”anjem uhranjenosti i pluÄne funkcije.Background. Exercise tolerance is compromised in many patients with cystic fibrosis (CF) and negatively affects their quality of life. The six-minute walk test (6MWT) can be used to assess exercise tolerance.
Aim. To investigate whether cystic fibrosis transmembrane conductance regulator (CFTR) modulators are associated with an improvement in exercise tolerance.
Methods. This is a retrospective study including children aged ā„ 5 years who began treatment with lumacaftor/ivacaftor (LUM/IVA) or elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) at the Cystic Fibrosis Centre for Children and Adults at the University Hospital Centre Zagreb in the period between 15. 10. 2021. and 30. 10. 2022. Patients were monitored during the first 12 months of treatment; every 3 months body mass index (BMI) was calculated and spirometry and 6MWT were performed. Collected data were analysed for a change in 6MWT results, BMI and percent-predicted FEV1 (ppFEV1) as well as correlation between these parameters. Missing values were replaced using imputation methods.
Results. 36 patients (median age 14 years) were included; 27 received ELX/TEZ/IVA and 9 received LUM/IVA. Average 6MWT walking distance (6MWD) prior to treatment and after 12 months were 522.1 Ā± 99.9 and 592.0 Ā± 106.3 m respectively (p < 0.001). Average increase in 6MWD in the first half-year was significantly higher than in the following 6 months (p = 0.023). Changes in BMI z-score (p = 0.006) and ppFEV1 (p < 0.001) during treatment were also significant. 6MWD at 12 months positively correlated with BMI z-score (p = 0.002) and ppFEV1 (p < 0.001).
Conclusions. Both clinically and statistically significant improvement in 6MWT results was visible following initiation of CFTR modulator treatment. A positive correlation with lung function improvement and improvement in BMI was observed
Novel Therapeutic Agents in Treatment of Alzheimerās Disease
Razvoj medicine produžio je ljudski životni vijek, ali poveÄanjem udjela starog stanovniÅ”tva raste i incidencija neurodegenerativnih bolesti kao Å”to je Alzheimerova bolest. Donedavno je jedina opcija za lijeÄenje Alzheimerove bolesti bila simptomatska terapija u obliku inhibitora kolinesteraze (rivastigmin, donepezil, galantamin) ili antagonista NMDA receptora (memantin). PokuÅ”aji pronalaska potencijalne terapije koja ne ublažava samo kliniÄku sliku, veÄ može i usporiti ili potpuno zaustaviti progresiju neuroloÅ”kog i kognitivnog propadanja, usmjereni su na dvije osnovne morfoloÅ”ke karakteristike bolesti ā amiloidne plakove i hiperfosforilirane tau neurofibrilarne snopiÄe, zbog Äega se naziva antiamiloidnom i antitau terapijom. Taj se terapijski pristup temelji na inhibiciji sinteze beta-amiloida ili proteina tau, sprjeÄavanju njihova taloženja u agregate ili uklanjanju nastalih patoloÅ”kih oblika primjenom specifiÄnih protutijela. Jedan takav lijek, aducunumab (originalno ime Aduhelm), nedavno je odobrio FDA za lijeÄenje blage Alzheimerove bolesti.The developments in the field of medicine have led to an increase in human lifespan, but with it comes the growth of older population which is followed by an increase in incidence of neurodegenerative diseases such as Alzheimerās disease. Until recently, the only available therapy for Alzheimerās disease was symptomatic in nature, such as the cholinesteraze inhibitors (rivastigmine, donepezil, galantamine) and the NMDA receptor antagonist memantine. Current attempts to find the potential disease-modifying therapy are targeting two typical morphological features of the disease, amyloid plaques and tau protein neurofibrillary tangles, which is why they are classified as anti-amyloid and anti-tau therapy. This approach is based on inhibition of beta-amyloid or tau protein synthesis, prevention of their aggregation or promotion of their clearence through use of specific antibodies. One such drug, aducunumab (brand name Aduhelm), has recently been approved by the FDA for treatment of mild Alzheimerās disease